AIM ImmunoTech (AIM) Liabilities and Shareholders Equity (2010 - 2026)

AIM ImmunoTech (AIM) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $8.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 37.4% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.0 million (down 45.67% YoY) and the FY2025 annual result came in at $5.8 million, down 32.83% from the prior year.
• Liabilities and Shareholders Equity grew to $8.6 million in Q1 2026, from $5.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $54.2 million in Q1 2022 to a low of $4.1 million in Q2 2025.
• A 5-year average of $23.2 million and a median of $16.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity sank 73.73% — and 2026, when it jumped 37.4%.
• Tracing AIM's Liabilities and Shareholders Equity over 5 years: stood at $40.5 million in 2022, then sank by 52.13% to $19.4 million in 2023, then plunged by 55.59% to $8.6 million in 2024, then tumbled by 32.83% to $5.8 million in 2025, then soared by 48.48% to $8.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $8.6 million (Q1 2026), $5.8 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.